Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis.
Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of
chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells
earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen
the invasiveness of surgical resection. This randomized multicenter phase III trial is
assessing whether preoperative chemotherapy improves oncologic outcomes of patients with
locally advanced colon cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Kyungpook National University Kyungpook National University Hospital